Literature DB >> 7546996

Assessment of magnetic resonance velocity mapping of global ventricular function during dobutamine infusion in coronary artery disease.

D J Pennell1, D N Firmin, P Burger, G Z Yang, C C Manzara, P J Ell, R H Swanton, J M Walker, S R Underwood, D B Longmore.   

Abstract

BACKGROUND: Magnetic resonance imaging (MRI) is a versatile technique for examination of the cardiovascular system but only recently has assessment of myocardial ischaemia in coronary artery disease (CAD) become possible, for example by demonstrating abnormalities of regional ventricular contraction during stress. Global ventricular function during stress was assessed by MRI of aortic flow, which has not been previously attempted.
DESIGN: Variables measured by MRI reflecting the effect of ischaemia on global ventricular function during dobutamine stress were correlated with thallium-201 myocardial perfusion tomography. PATIENTS: 10 normal controls and 25 patients with CAD.
SETTING: Tertiary cardiac referral centre.
METHODS: Novel MRI sequences and analysis systems were used to measure the following variables during staged dobutamine infusion to 20 micrograms/kg/min: stroke volume, cardiac output, cardiac power output, peak flow, peak flow acceleration, aortic back flow, and flow wave velocity. Heart rate, blood pressure, double product, and maximum tolerated dobutamine dose were also measured. Multiple regression analysis was used to compare changes during stress with 201TI tomography.
RESULTS: All parameters except for stroke volume and diastolic blood pressure increased in the controls. In the patients with CAD a significant relation was shown between the extent of reversible ischaemia and the change in peak flow acceleration (P < 0.00001), peak flow (P = 0.002), cardiac power output (P = 0.036), maximum dobutamine dose (P = 0.039), and systolic blood pressure (P = 0.04). Peak flow acceleration accounted for 58.4% of the variation in reversible ischaemia, and after allowing for this, only cardiac power output remained independently predictive adding a further 4.2% to the model (adjusted r2 = 0.626). A decrease in peak flow acceleration with an increase in dobutamine infusion indicated moderate or severe ischaemia (chi 2 = 10.2, P = 0.017).
CONCLUSION: MRI may be used to assess variables of aortic flow during stress, which includes acceleration with high temporal resolution. Peak flow acceleration was the most sensitive indicator of the effect of ischaemia on global ventricular function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7546996      PMCID: PMC483993          DOI: 10.1136/hrt.74.2.163

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  40 in total

1.  Studies of Doppler aortic flow velocity during supine bicycle exercise.

Authors:  J M Gardin; J Kozlowski; A Dabestani; M Murphy; C Kusnick; A Allfie; D Russell; W L Henry
Journal:  Am J Cardiol       Date:  1986-02-01       Impact factor: 2.778

2.  Ascending aortic blood velocity and acceleration using Doppler ultrasound in the assessment of left ventricular function.

Authors:  E D Bennett; S A Barclay; A L Davis; D Mannering; N Mehta
Journal:  Cardiovasc Res       Date:  1984-10       Impact factor: 10.787

3.  Magnetic resonance imaging of coronary arteries: technique and preliminary results.

Authors:  D J Pennell; J Keegan; D N Firmin; P D Gatehouse; S R Underwood; D B Longmore
Journal:  Br Heart J       Date:  1993-10

4.  Evaluation of left ventricular function during upright exercise: correlation of exercise Doppler with postexercise two-dimensional echocardiographic results.

Authors:  A A Mehdirad; G A Williams; A J Labovitz; R J Bryg; B R Chaitman
Journal:  Circulation       Date:  1987-02       Impact factor: 29.690

5.  Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography.

Authors:  R S Gibson; D D Watson; G B Craddock; R S Crampton; D L Kaiser; M J Denny; G A Beller
Journal:  Circulation       Date:  1983-08       Impact factor: 29.690

6.  Value of left ventricular ejection fraction during exercise in predicting the extent of coronary artery disease.

Authors:  N L DePace; A S Iskandrian; A H Hakki; S A Kane; B L Segal
Journal:  J Am Coll Cardiol       Date:  1983-04       Impact factor: 24.094

7.  Real-time radionuclide cineangiography in the noninvasive evaluation of global and regional left ventricular function at rest and during exercise in patients with coronary-artery disease.

Authors:  J S Borer; S L Bacharach; M V Green; K M Kent; S E Epstein; G S Johnston
Journal:  N Engl J Med       Date:  1977-04-14       Impact factor: 91.245

8.  Effect of coronary artery disease on Doppler-derived parameters of aortic flow during upright exercise.

Authors:  R J Bryg; A J Labovitz; A A Mehdirad; G A Williams; B R Chaitman
Journal:  Am J Cardiol       Date:  1986-07-01       Impact factor: 2.778

9.  Doppler echocardiographic measurement of flow velocity in the ascending aorta during supine and upright exercise.

Authors:  P J Daley; K B Sagar; L S Wann
Journal:  Br Heart J       Date:  1985-12

10.  Usefulness of noninvasive Doppler measurement of ascending aortic blood velocity and acceleration in detecting impairment of the left ventricular functional response to exercise three weeks after acute myocardial infarction.

Authors:  N Mehta; D Bennett; D Mannering; K Dawkins; D E Ward
Journal:  Am J Cardiol       Date:  1986-11-01       Impact factor: 2.778

View more
  2 in total

1.  The seismocardiogram as magnetic-field-compatible alternative to the electrocardiogram for cardiac stress monitoring.

Authors:  M Jerosch-Herold; J Zanetti; H Merkle; L Poliac; H Huang; A Mansoor; F Zhao; N Wilke
Journal:  Int J Card Imaging       Date:  1999-12

2.  Simplified detection of myocardial ischemia by seismocardiography. Differentiation between causes of altered myocardial function.

Authors:  M Becker; A B Roehl; U Siekmann; A Koch; M de la Fuente; R Roissant; K Radermacher; N Marx; M Hein
Journal:  Herz       Date:  2013-06-23       Impact factor: 1.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.